Revenue grew 6% year-over-year to $339 million, with all core platforms contributing to profitable growth and adjusted EPS up 4%. Guidance for FY27 was raised, reflecting strong plasma and MedSurg performance, robust cash flow, and continued innovation, while maintaining a disciplined outlook.Based…
Net revenues rose 5.6% to $339.4 million, with operating income up 6.7% and net income at $33.0 million, impacted by a higher tax rate. The company completed a major segment realignment, acquired Vivasure Medical, and continued share repurchases and debt management, maintaining strong liquidity.Ori…
Blood products company Haemonetics NYSE:HAEwill be reporting results this Thursday before market open. Here’s what to look for.Haemonetics beat analysts’ revenue expectations last quarter, reporting revenues of $346.4 million, up 4.8% year on year. It was a very strong quarter for the company, with…
Haemonetics elected Martin Madaus as a director, effective July 24, 2026, with expected appointments to the Audit Committee and the Governance and Compliance Committee.Original SEC Filing: HAEMONETICS CORP [ HAE ] - 8-K - Jul. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Cons…
BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results an…
Haemonetics Corporation’s HAE impressive Plasma franchise is poised to drive growth in the upcoming quarters. The robust uptake of the NexSys PCS system bodes well for its long-term growth. However, a debt-burdened balance sheet and fierce competitive pressure remain concerns for HAE’s operations.I…
